{"entity":{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","aka":["Olema Pharmaceuticals, Inc."],"tldr":"Olema Pharmaceuticals is a United States-based biotechnology company running 2 late-stage cancer trials in HR-positive / HER2-negative breast cancer.","summary":"Olema Pharmaceuticals, based in San Francisco, the United States, is a biotechnology company listed as NASDAQ: OLMA. Olema Oncology is a clinical-stage biopharmaceutical company focused on discovering, developing and commercialising targeted therapies for breast cancer, drawing on expertise in endocrine-driven cancers and nuclear receptors. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in HR-positive / HER2-negative breast cancer. The largest, NCT07085767 (Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer), plans to enrol 1000 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.olema.com"},{"label":"ClinicalTrials.gov: trials led by Olema Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=Olema%20Pharmaceuticals%2C%20Inc."},{"label":"Pipeline page","url":"https://www.olema.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["ribociclib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06016738","nct07085767"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco","country":"US","companyType":"biotech","website":"https://www.olema.com","ticker":"NASDAQ: OLMA","founded":2006,"stage":"public","investors":[],"funding":[]},"route":"/companies/olema-pharmaceuticals/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"trial":[{"id":"nct06016738","kind":"trial","name":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct06016738/"},{"id":"nct07085767","kind":"trial","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct07085767/"}]}}